Cited by 655Medication Adherence and ComplianceDiabetes Management and EducationDiabetes Management and Research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Open access

Peyrot, M., Barnett, A. H., Meneghini, L. F., Schumm‐Draeger, P.‐M.·2012·Diabetic Medicine

DOI 10.1111/j.1464-5491.2012.03605.xPMC PMC3433794

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: To examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens. METHODS: Internet survey of 1250 physicians (600 specialists, 650 primary care physicians) who treat patients with diabetes and telephone survey of 1530 insulin-treated patients (180 with Type 1 diabetes, 1350 with Type 2 diabetes) in China, France, Japan, Germany, Spain, Turkey, the UK or the USA. RESULTS: One third (33.2%) of patients reported insulin omission/non-adherence at least 1 day in the last month, with an average of 3.3 days. Three quarters (72.5%) of physicians report that their typical patient does not take their insulin as prescribed, with a mean of 4.3 days per month of basal insulin omission/non-adherence and 5.7 days per month of prandial insulin omission/non-adherence. Patients and providers indicated the same five most common reasons for insulin omission/non-adherence: too busy; travelling; skipped meals; stress/emotional problems; public embarrassment. Physicians reported low patient success at initiating insulin in a timely fashion and adjusting insulin doses. Most physicians report that many insulin-treated patients do not have adequate glucose control (87.6%) and that they would treat more aggressively if not for concern about hypoglycaemia (75.5%). Although a majority of patients (and physicians) regard insulin treatment as restrictive, more patients see insulin treatment as having positive than negative impacts on their lives. CONCLUSIONS: Glucose control is inadequate among insulin-treated patients, in part attributable to insulin omission/non-adherence and lack of dose adjustment. There is a need for insulin regimens that are less restrictive and burdensome with lower risk of hypoglycaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03605.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

FIGURE 1 Physician report: patient success with insulin treatment tasks (n = 1250)*†. *Percentage of physicians reporting that their patients are very successful (vs. somewhat successful, not very successful, not at all successful, ‘don’t know’). †Specialists and primary care physicians not significantly different for any measureCC BY · PubMed Central

FIGURE 2 Patient reports: impact of insulin treatment on life domains in patients with Type 1 (non-hatched) and Type 2 (hatched) diabetes mellitus (n = 1530). *Positive and negative responses differ significantly (P < 0.05); †reports from patients with Type 1 and Type 2 diabetes differ significantly (P < 0.05).CC BY · PubMed Central

FIGURE 3 Physician beliefs about insulin treatment (n = 1250). *Strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree, neither, ‘don’t know’); †strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree)CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study
Peyrot, M., Rubin, R. R., Lauritzen, T., Snoek, F. J., Matthews, D. R., & Skovlund, S. E. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01644.x · Cited by 931
Self-citation
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M. F., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 784
Self-citation
Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Self-citation
Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus
Rubin, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.012 · Cited by 403
Psychological insulin resistance: patient beliefs and implications for diabetes management
Brod, M. I., Kongsø, J. H., Alolga, S. L., & Christensen, T. L. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9419-1 · Cited by 238
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers
Nakar, S., Yitzhaki, G., Rosenberg, R., & Vinker, S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.02.004 · Cited by 159

Show all 22 references

Sorted by citations

Items 201–300 of 655

Model for Simulating Fasting Glucose in Type 2 Diabetes and the Effect of Adherence to Treatment
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., Kildegaard, J., Orden, B. V., & Jørgensen, J. B. (2017) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2017.08.2527 · Cited by 20
Glargine-300: An updated literature review on randomized controlled trials and real-world studies
Ghosh, S. K., & GHOSH, R. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i4.100 · Cited by 20
Machine Learning-Based Adherence Detection of Type 2 Diabetes Patients on Once-Daily Basal Insulin Injections
Thyde, D. N., Mohebbi, A., Bengtsson, H. L., Jensen, M. L., & Mørup, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820912411 · Cited by 24
Hypoglycemia and diabetes: increased need for awareness
Shaefer, C. F., Hinnen, D., & Sadler, C. E. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1163255 · Cited by 21
Patient and Provider Perspectives on Glaucoma Treatment Adherence: A Delphi Study in Urban Alabama
Poleon, S., Racette, L., Fifolt, M. M., Schoenberger, Y., Abu, S. L., & Twa, M. D. (2021) · Optometry and Vision Science · doi:10.1097/opx.0000000000001776 · Cited by 19
pH‐Responsive Hexa‐Histidine Metal Assembly (HmA) with Enhanced Biocatalytic Cascades as the Vehicle for Glucose‐Mediated Long‐Acting Insulin Delivery
Zhou, S., Yang, R., Xie, X., Wang, L., Zheng, S., Li, N., Tang, S., & Zan, X. (2023) · Advanced Science · doi:10.1002/advs.202301771 · Cited by 19
A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9–15%: DUAL HIGH Trial
Galindo, R. J., Moazzami, B., Scioscia, M. F., Zambrano, C., Albury, B. S., Saling, J., Vellanki, P., Pasquel, F. J., Davis, G. M., Fayfman, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2426 · Cited by 19
Insulin Administration and the Impacts of Forgetting a Dose
Brod, M. I., Pohlman, B., & Kongsø, J. H. (2013) · Patient · doi:10.1007/s40271-013-0029-9 · Cited by 19
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
Freemantle, N., Mauricio, D., Giaccari, A., Bailey, T. S., Roussel, R., Franco, D. R., Berthou, B., Pilorget, V., Westerbacka, J., Bosnyák, Z., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1708287 · Cited by 19
Impact of pharmacist insulin injection re-education on glycemic control among type II diabetic patients in primary health clinics
Selvadurai, S., Cheah, K. Y., Ching, M. W., Kamaruddin, H., Lee, X. Y., Ngajidin, R. M., Lee, X. H., & Ali, L. M. M. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.04.028 · Cited by 18
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries
Fulcher, G. R., Akhtar, S., Aljaser, S., Medina, J., Mohamed, M., Nicodemus, N. A., Olsen, A. H., Singh, K. P., & Kok, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02212-3 · Cited by 20
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
Miccoli, R., Dardano, A., Bianchi, C., & Prato, S. D. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40097 · Cited by 18
Ambulatory glucose profile (AGP): utility in UK clinical practice
Evans, M. L., CRANSTON, I. C., & Bailey, C. J. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.121 · Cited by 18
Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch
Peyrot, M. F., Dreon, D. M., Zraick, V., Cross, B., & Tan, M. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0365-1 · Cited by 18
Self-citation
Level of insulin adherence among diabetes mellitus patients in Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia, 2017: a cross-sectional study
Tewabe, T., & Kindie, S. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3398-2 · Cited by 18
Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study
Brixner, D. I., Ermakova, A., Xiong, Y., Sieradzan, R., Sacks, N. C., Cyr, P. L., & Taylor, S. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.12.014 · Cited by 18
Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis
Stuckey, H. L., Fisher, L., Polonsky, W. H., Hessler, D., Snoek, F. J., Tang, T. S., Hermanns, N., Mundet, X., da Silva, M. E. R., Sturt, J. A., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000723 · Cited by 19
Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin
Yang, J. F., Gong, X., Bakh, N. A., Carr, K. M., Phillips, N. F. B., Ismail‐Beigi, F., Weiss, M. A., & Strano, M. S. (2020) · Diabetes · doi:10.2337/db19-0879 · Cited by 19
Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
Chan, W. B., Chen, J.-F., Goh, S., Vũ, T. T. H., Isip-Tan, I. T., Mudjanarko, S. W., Bajpai, S., Mabunay, M. A., & Bunnag, P. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s143046 · Cited by 18
Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes
HIGHTON, P. J., Funnell, M. P., Gupta, P., Zaccardi, F., Lim, L., Seidu, S., & Khunti, K. (2025) · Diabetologia · doi:10.1007/s00125-025-06617-x · Cited by 26
Concepts and clinical use of ultra-long basal insulin
Eliaschewitz, F. G., & Barreto, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0117-1 · Cited by 17
Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes
Edwards, S., He, X., Wang, W., Poon, J. L., Meadows, E. S., Price, D. A., Johnson, J. L., Wolpert, H. A., & Polonsky, W. H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0239 · Cited by 17
Insulin analogs in the treatment of type II diabetes and future perspectives
Sebastian, S. A., Co, E. L., Mehendale, M., & Hameed, M. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101417 · Cited by 17
Improving Medication Adherence Among Patients With Type 2 Diabetes
Meece, J. D. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190013513803 · Cited by 17
Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
Ericsson, Å., Glah, D. R., Lorenzi, M. F., Jansen, J. P., & Fridhammar, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191953 · Cited by 17
Adherence to Premixed Insulin in a Prefilled Pen Compared With a Vial/Syringe in People With Diabetes in Singapore
Cheen, M. H. H., Lim, S. H., Huang, M. C., Bee, Y. M., & Wee, H. L. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.009 · Cited by 17
A New Option for Glycemic Control: Insulin Degludec, a New‐Generation Basal Insulin with an Ultralong Duration of Action
Drab, S. R., & Philis‐Tsimikas, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1361 · Cited by 17
Diabetes Patients' Experiences With the Implementation of Insulin Therapy and Their Perceptions of Computer-Assisted Self-Management Systems for Insulin Therapy
Simon, A. C. R., Gude, W. T., Holleman, F., Hoekstra, J. B. L., & Peek, N. B. (2014) · Journal of Medical Internet Research · doi:10.2196/jmir.3198 · Cited by 17
Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin
Wang, T., Conrad, K. A., Brunt, K. V., & Rees, T. M. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633232 · Cited by 17
Rational Design of Glucose‐Responsive Insulin Using Pharmacokinetic Modeling
Bakh, N. A., Bisker, G., Lee, M. A., Gong, X., & Strano, M. S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700601 · Cited by 17
Insulin glargine 300 U/ mL and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues
CHENG, A. Y. Y., Bailey, T. S., Mauricio, D., & Roussel, R. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3329 · Cited by 16
The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database
Eby, E. L., Bajpai, S., Faries, D. E., Haynes, V. S., & Lage, M. J. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1081 · Cited by 16
Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study
Wu, J., Morrison, F. J. R., Zhao, Z., Haynes, G., He, X., Ali, A. K., Shubina, M., Malmasi, S., Ge, W., Peng, X., et al. (2021) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00115-2 · Cited by 16
Barriers and Attitudes of Primary Healthcare Physicians to Insulin Initiation and Intensification in Saudi Arabia
Alhagawy, A. J., Yafei, S., Hummadi, A. A., Abutaleb, R., Hakamy, M., Alzughbi, T., Gharawi, N., Moafa, M., Mokali, A., Alhiqwy, I., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416794 · Cited by 16
Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review
Sparre, T., Hammershøy, L., Steensgaard, D. B., Sturis, J., Vikkelsøe, P., & Azzarello, A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221145201 · Cited by 17
Current evidence for designing self-management support for underserved populations: an integrative review using the example of diabetes
Litchfield, I. J., Barrett, T. G., Hamilton-Shield, J. P., Moore, T. H., Narendran, P., Redwood, S., Searle, A., Uday, S., Wheeler, J., & Greenfield, S. (2023) · International Journal for Equity in Health · doi:10.1186/s12939-023-01976-6 · Cited by 18
Self-management of type 1 diabetes in young adults: Is it impeded by aspects of everyday life? A scoping review
Shiel, E. V., Hemingway, S., Burton, K. A., & KING, N. M. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102918 · Cited by 16
Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges
Emad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 24
Clinical use of the co-formulation of insulin degludec and insulin aspart
Kumar, A., Awata, T., Bain, S. C., Ceriello, A., Fulcher, G. R., Unnikrishnan, A., Arechavaleta, R., González-Gálvez, G., Hirose, T., Home, P., et al. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12821 · Cited by 16
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 17
Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., & Schmitt, H. (2017) · Diabetic Medicine · doi:10.1111/dme.13390 · Cited by 16
Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
Lindauer, K., & Becker, R. H. A. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203269 · Cited by 16
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
Patel, D. K., Triplitt, C. L., & Trujillo, J. M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00907-8 · Cited by 16
Public Perspectives on Anti-Diabetic Drugs: Exploratory Analysis of Twitter Posts
Golder, S., Bach, M., O’Connor, K., Gross, R., Hennessy, S., & Gonzalez‐Hernandez, G. (2020) · JMIR Diabetes · doi:10.2196/24681 · Cited by 15
Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey
Perez‐Nieves, M., Ivanova, J. I., Hadjiyianni, I., Zhao, C., Cao, D., Schmerold, L. M., Kalirai, S., King, S. B., DeLozier, A. M., Birnbaum, H. G., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1341403 · Cited by 16
Self-citation
The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes
Haluzı́k, M., Fulcher, G., Pieber, T. R., Bardtrum, L., Tutkunkardas, D., & Rodbard, H. W. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13261 · Cited by 16
First real-world experience with bigfoot unity: a 6-month retrospective analysis
Baliga, B. S., Tillman, J. B., Olson, B., Vaughan, S., Sheikh, F. N., & Malone, J. K. (2023) · Clinical Diabetes · doi:10.2337/cd22-0126 · Cited by 15
The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting
Drummond, R. S., Malkin, S. J. P., Preez, M. D., Lee, X. Y., & Hunt, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13375 · Cited by 15
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K. K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis
Gimeno, E. J., Bøgelund, M., Larsen, S., Okkels, A., Reitzel, S. B., Ren, H., & Orozco‐Beltrán, D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01559-w · Cited by 21
Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
Hadjiyianni, I., Desai, U. S., Suzuki, S., Ivanova, J. I., Cao, D., Kirson, N. Y., Chida, D., Enloe, C. J., Birnbaum, H. G., & Perez‐Nieves, M. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0215-6 · Cited by 14
Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
Kvapil, M., Prázný, M., Holik, P., Rychna, K., & Hunt, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0323-y · Cited by 14
Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin
Johnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 15
Willingness of people with Type 2 diabetes to start insulin therapy: Evidence from the South African Tshwane Insulin Project (TIP)
Piotie, P. N., Wood, P. S., Webb, E. M., Marcus, T. S., & Rheeder, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108366 · Cited by 15
Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM
Kawaguchi, Y., Miyamoto, S., Hajika, Y., Ashida, N., Hirota, T., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02138-w · Cited by 15
Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments
Wei, W., Jiang, J. Z., Lou, Y., Ganguli, S., & Matusik, M. S. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.16227 · Cited by 15
Wirelessly Controlled Implantable System for On-demand and Pulsatile Insulin Administration
Lee, S. H., Ahn, J. W., Cho, Y. C., Kim, S.-N., Lee, C., Ku, G., Choy, Y. B., & Kim, H. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-41430-8 · Cited by 15
A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies
AGREEMENT Investigators, Liatis, S., Iraklianou, S., Kazakos, K., Mastorakos, G. P., Milios, K., Mouslech, Z., Noutsou, M., Pagkalos, E. M., & Sampanis, C. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0364-5 · Cited by 14
Glucose-Responsive Microspheres as a Smart Drug Delivery System for Controlled Release of Insulin
Yu, J., Wang, Q., Liu, H., Shan, X., Pang, Z., Song, P., Niu, F., & Hu, L. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00588-2 · Cited by 15
Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization
Dalal, M. R., Kazemi, M. R., & Ye, F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1248911 · Cited by 14
Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
Hubálek, F., Cramer, C. N., Helleberg, H., Johansson, E., Nishimura, E., Schluckebier, G., Steensgaard, D. B., Sturis, J., & Kjeldsen, T. (2024) · Nature Communications · doi:10.1038/s41467-024-50477-9 · Cited by 20
The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes
Lajara, R., Cengiz, E., & Tanenberg, R. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1298522 · Cited by 14
Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system
Psota, M., Psenkova, M., Racekova, N., de Arellano, A. R., Vandebrouck, T., & Hunt, B. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s143127 · Cited by 13
Carbohydrate knowledge, lifestyle and insulin: an observational study of their association with glycaemic control in adults with type 1 diabetes
Smythe, K., Saw, M., Mak, M., & Wong, V. (2018) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12561 · Cited by 14
Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes
Lauffenburger, J. C., Lewey, J., Jan, S., Lee, J., Ghazinouri, R., & Choudhry, N. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19645 · Cited by 14
Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review
Boye, K. S., Shinde, S., Kennedy-Martin, T., Robinson, S., & Thieu, V. T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s328583 · Cited by 16
Predictors of Clinical Inertia and Type 2 Diabetes: Assessment of Primary Care Physicians and Their Patients
Isajev, N., Bjegovic-Mikanovic, V. M., Bukumirić, Z., Vrhovac, D., & Lalic, N. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084436 · Cited by 14
Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review
Boye, K. S., Shinde, S., Kennedy‐Martin, T., Robinson, S. J., & Thieu, V. T. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 14
The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin
Shaefer, C. F., & Anderson, J. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1103640 · Cited by 14
Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial
Kadowaki, T., Jinnouchi, H., Kaku, K., Hersløv, M. L., Hyllested-Winge, J. L., & Nakamura, S. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12502 · Cited by 14
Insulin/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one?
Aroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
Outcomes and healthcare resource utilization associated with medically attended hypoglycemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting
Escalada, J., Liao, L., Pan, C., Wang, H., & BALA, M. M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1189893 · Cited by 13
Assessment of Adherence to Insulin Injections among Diabetic Patients on Basal-Bolus Regimen in Primary and Secondary Healthcare Centers in Al-Jouf Region of Saudi Arabia; A Descriptive Analysis
Alsaidan, A. A., Alsaidan, O. A., Mallhi, T. H., Khan, Y. H., Alzarea, A. I., & Alanazi, A. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103474 · Cited by 19
Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative Review
Brixner, D. I., Edelman, S. V., Sieradzan, R., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01598-3 · Cited by 14
Role of Patient and Practice Characteristics in Variance of Treatment Quality in Type 2 Diabetes between General Practices
Cho, Y. Y., Sidorenkov, G. A., & Denig, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166012 · Cited by 13
Psychosocial aspects and contributions of behavioural science to medication‐taking for adults with type 2 diabetes
Winkley, K., Upsher, R. J., Polonsky, W. H., & Holmes‐Truscott, E. (2019) · Diabetic Medicine · doi:10.1111/dme.14214 · Cited by 16
Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study
Cho, Y. K., Lee, J., Kim, H. S., Park, J., Jung, C. H., & Lee, W. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00881-3 · Cited by 13
Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study
Liu, S.-C., Lee, C.-C., Chuang, S., Sun, F., & Zeng, Y.-H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.001 · Cited by 13
Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems
Wang, H., Zhou, Y., Wang, Y., Cai, T., Hu, Y., Jing, T., Ding, B., Su, X., Li, H., & Ma, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.791439 · Cited by 13
Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study
de Lusignan, S., McGovern, A. P., Hinton, W., Whyte, M., Munro, N. M., Williams, E. D., Marcu, A., Williams, J., Ferreira, F. M., Mount, J., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01306-z · Cited by 13
The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System
Parekh, W., Streeton, S. E., Baker‐Knight, J., Montagnoli, R., Nicoziani, P., & Marchesini, G. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0418-0 · Cited by 13
Decisional Balance for Insulin Injection: Scale Development and Psychometric Testing
Hsu, H., Chen, S., Huang, Y., Wang, R., Lee, Y., & An, L.-W. (2019) · Journal of Nursing Research · doi:10.1097/jnr.0000000000000316 · Cited by 13
Clinical Insights Into a New, Disposable Insulin Delivery Device
Knutsen, P. G., Voelker, C. Q., & NIKKEL, C. C. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.209 · Cited by 13
Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures
Holmes‐Truscott, E., Pouwer, F., & Speight, J. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0873-4 · Cited by 13
Acceptability of community health worker and peer supported interventions for ethnic minorities with type 2 diabetes: a qualitative systematic review
Grant, V., & Litchfield, I. J. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1306199 · Cited by 12
Design and characterization of 3D-printed hollow microneedle arrays for transdermal insulin delivery
Zhang, S., Sims, J., Mehochko, I., Zolovick, R., Kwak, T., & Staples, A. (2024) · AIP Advances · doi:10.1063/5.0204216 · Cited by 12
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
Pollock, R. F., Valentine, W. J., Marso, S. P., Gundgaard, J., Hallén, N., Hansen, L., Tutkunkardas, D., Buse, J. B., & On behalf of the DEVOTE Study Group (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0430-4 · Cited by 12
Comparison of three algorithms for initiation and titration of insulin glargine in insulin‐naive patients with type 2 diabetes mellitus (既往从未使用过胰岛素的2型糖尿病患者使用三种不同的启用与滴定甘精胰岛素剂量方案的比较)
DAILEY, G. E., Aurand, L. A., Stewart, J. A., Ameer, B., & Zhou, R. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12080 · Cited by 12
Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden
Olofsson, S., Norrlid, H., & Persson, U. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1187152 · Cited by 12
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
Evans, M., Moes, R. G. J., Pedersen, K. S., Gundgaard, J., & Pieber, T. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01332-y · Cited by 12
High cervical intravagal hypercellular parathyroid gland as the etiology of severe persistent primary hyperparathyroidism.
Jf, B., Dl, F., Doppman, J., Shawker, T. H., Skarulis, M. C., Am, S., Sj, M., & Hr, A. (1995) · PubMed · Cited by 12
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
Vilsbøll, T., Vora, J. P., Jarlov, H., Kvist, K., & Blonde, L. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0376-0 · Cited by 11
Elucidating factors associated with non-adherence among Type 1 diabetes patients in primary care setting in Southeastern Brazil
Peres, H. A., Pereira, L. R. L., Martínez, E. Z., Viana, C. M., & Foss‐Freitas, M. C. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.06.002 · Cited by 10
Knowledge, attitude and practices of insulin therapy among patients with type 2 diabetes: a cross-sectional study
Almheiri, A., Binjab, E. A., Albloushi, M. M., Alshamsi, M. T., Khansaheb, H. H., Zidan, M. A., & Hassoun, A. A. K. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079693 · Cited by 11
Pain and Satisfaction among Type 2 Diabetic Patients: Effects of Coughing, ShotBlocker and Vibration during Insulin Injection: A Randomised Controlled Trial
Abdulyemmah, A. D., & Majeed, H. M. (2025) · Nigerian Postgraduate Medical Journal · doi:10.4103/npmj.npmj_55_25 · Cited by 11
Differences between patient and physician opinions on adherence to medication for hypertension and diabetes mellitus
Liguori, Y., Murase, K., & Hamamura, M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1189408 · Cited by 11
Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial
Lewey, J., Wei, W., Lauffenburger, J. C., Makanji, S. S., Chant, A., DiGeronimo, J., Nanchanatt, G., Jan, S., & Choudhry, N. K. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016551 · Cited by 11
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study ( EU ‐ TREAT )
Knudsen, S. T., Lapolla, A., Schultes, B., Tentolouris, N., Catarig, A., Wolden, M. L., & Siegmund, T. (2019) · Diabetic Medicine · doi:10.1111/dme.13976 · Cited by 11
Barriers of Doctors and Patients in Starting Insulin for Type 2 Diabetes Mellitus
Alidrisi, H. A., Bohan, A., & Mansour, A. A. (2021) · Cureus · doi:10.7759/cureus.18263 · Cited by 11
Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
Wiesli, P., & Schories, M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0518-x · Cited by 11

Authors: Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐.
Affiliations: Johns Hopkins University (US)
Heart of England NHS Foundation Trust (GB)
University of Miami (US)
München Klinik Bogenhausen (DE)
Corresponding author: Peyrot, M.
ORCID: Peyrot, M.
Meneghini, L. F.
Venue: Diabetic Medicine
Publisher: Wiley
Published: 2012-04-16
Volume: 29
Issue: 5
Pages: 682-689
ISSN: 0742-3071 (ISSN-L)
1464-5491
DOI: 10.1111/j.1464-5491.2012.03605.x
PMC: PMC3433794
OpenAlex: W1613501644
Cited by: 655
References: 22
Citations by year: 2026: 29 · 2025: 41 · 2024: 61 · 2023: 43 · 2022: 42 · 2021: 43 · 2020: 53 · 2019: 49 · 2018: 52 · 2017: 48 · 2016: 52 · 2015: 50 · 2014: 46 · 2013: 35 · 2012: 8
FWCI: 38.62
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetic Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: insulin therapy, insulin adherence, insulin omission, barriers to adherence, patient beliefs, physician beliefs, type 1 diabetes, type 2 diabetes, glycemic control, hypoglycemia, basal insulin, prandial insulin, insulin dose adjustment
MeSH terms: Assessment of Medication Adherence, Blood Glucose, China, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, France, Germany, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Japan, Male, Middle Aged, Spain, Turkey, United States, Health Behavior, Drug Monitoring, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks